Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 3, 2010, Pages 482-488

  Bouman, H J ^a   Parlak, E ^a   Van Werkum, J W ^a   Breet, N J ^a   Ten Cate, H ^a,b   Hackeng, C M ^a   Ten Berg, J M ^a   Taubert, D ^c  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Active metabolite; Clopidogrel; Monitoring; Pharmacokinetics; Platelet function test; Responsiveness

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; FUNCTION TEST; HUMAN; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TANDEM MASS SPECTROMETRY; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOTRANSFORMATION; BLOOD PLATELETS; CELL ADHESION MOLECULES; CHROMATOGRAPHY, LIQUID; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; HUMANS; LINEAR MODELS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RECEPTORS, PURINERGIC P2; TANDEM MASS SPECTROMETRY; TICLOPIDINE;

EID: 77949297362     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03733.x     Document Type: Article

References (26)

1. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000, 84:891-6.
2. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409:202-7.
3. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-51.
4. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-62.
5. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
6. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-42.
7. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-7.
8. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53:849-56.
9. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006, 27:2420-5.
10. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51:1404-11.
11. van Werkum JW, Topcu Y, Postma S, Kelder JC, Hackeng CM, ten Berg JM, Verheugt FW. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008, 99:637-9.
12. van Werkum JW, Hackeng CM, Smit JJ, van't Hof AW, Verheugt F, ten Berg JM. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2008, 8:33-55.
13. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 2008, 48:1219-24.
14. Sibbing D, Taubert D, Schomig A, Kastrati A, von Beckerath N. Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost 2008, 6:1230-2.
15. van Werkum JW, Kleibeuker M, Mieremet N, ten Berg JM, Hackeng CM. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? J Thromb Haemost 2007, 5:884-6.
16. Goto S, Tamura N, Ishida H, Ruggeri ZM. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5′-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 2006, 47:155-62.
17. Ivandic BT, Schlick P, Staritz P, Kurz K, Katus HA, Giannitsis E. Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor. Clin Chem 2006, 52:383-8.
18. Shenkman B, Matetzky S, Fefer P, Hod H, Einav Y, Lubetsky A, Varon D, Savion N. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res 2008, 122:336-45.
19. van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-to-head comparison between the VerifyNowP2Y12-assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J Thromb Haemost 2006, 4:2516-8.
20. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schömig A, Schömig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004, 92:311-6.
21. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008, 117:261-95.
22. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006, 28:315-22.
23. van Werkum JW, van der Stelt CA, Seesing TH, ten Berg JM, Hackeng CM. The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 2007, 5:881-3.
24. Aleil B, Meyer N, Cazenave JP, Mossard JM, Gachet C. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost 2005, 94:886-7.
25. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-13.
26. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that pre-existent variability in platelet response to ADP accounts for " clopidogrel resistance" J Thromb Haemost 2007, 5:75-81.